$4.25 -0.02 (%) Xoma Corp - NASDAQ

Sep. 30, 2014 | 10:08 AM

Partner Headlines

  1. MLV & Co Has Positive Outlook On XOMA

    Benzinga | Aug. 8, 2014 | 10:00AM EST
  2. Morning Market Movers

    Benzinga | Apr. 29, 2014 | 09:43AM EST
  3. UPDATE: MLV & Co Upgrades XOMA on Valuation

    Benzinga | Apr. 29, 2014 | 07:56AM EST
  4. XOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum

    Benzinga | Apr. 28, 2014 | 09:03AM EST
  5. Benzinga's Top Downgrades

    Benzinga | Mar. 11, 2014 | 08:35AM EST
  6. UPDATE: MLV & Co Downgrades XOMA on Valuation/Sentiment

    Benzinga | Mar. 11, 2014 | 08:14AM EST
  7. Mid-Afternoon Market Update: FuelCell Energy Hangs on to Gains as Canadian Solar Shares Fall on Poor Report

    Benzinga | Mar. 5, 2014 | 15:27PM EST
  8. Mid-Day Market Update: Smith & Wesson Surges On Upbeat Results; XOMA Shares Drop

    Benzinga | Mar. 5, 2014 | 13:19PM EST
  9. Mid-Morning Market Update: Markets Mostly Flat; Brown-Forman Posts Higher Profit

    Benzinga | Mar. 5, 2014 | 10:22AM EST
  10. Morning Lowers for Mar. 5, 2014: XOMA, USU, CSIQ, AUDC, RATE

    Benzinga | Mar. 5, 2014 | 10:14AM EST
  11. Benzinga's Top #PreMarket Losers

    Benzinga | Mar. 5, 2014 | 08:13AM EST
  12. UPDATE: XOMA Offers Update on Gevokizumaba, Says Results Do Not Support Movement to Pivotal Development Trial

    Benzinga | Mar. 4, 2014 | 16:42PM EST
  13. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

    Benzinga | Feb. 25, 2014 | 09:41AM EST
  14. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 13, 2014 | 10:50AM EST
  15. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 2, 2014 | 08:20AM EST
  16. XOMA Announces Closing of the Offering and Exercise of 1.425M Share Over Allotment Option

    Benzinga | Dec. 18, 2013 | 16:04PM EST
  17. XOMA Announces Pricing of 9.5M Shares at $5.25 per Share

    Benzinga | Dec. 13, 2013 | 09:15AM EST
  18. XOMA Prices 9.5M Share Offering at $5.25/Share

    Benzinga | Dec. 13, 2013 | 09:15AM EST
  19. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 13, 2013 | 08:38AM EST
  20. Benzinga's Top #PreMarket Gainers

    Benzinga | Oct. 31, 2013 | 08:13AM EST
  21. Xoma Shares Rise 6% After-Hours on Encouraging Phase 2 Gevokizumab Results

    Benzinga | Oct. 30, 2013 | 16:57PM EST
  22. XOMA Shares Quiet Following Results of Two Phase 2 Trials Showing Gevokizumab Program 'Very Encouraging,' 'Compelling'

    Benzinga | Oct. 30, 2013 | 16:50PM EST
  23. UPDATE: Piper Jaffray Initiates XOMA at Overweight on 'Xciting Antibody Play'

    Benzinga | Aug. 13, 2013 | 08:40AM EST
  24. Benzinga's Top Initiations

    Benzinga | Aug. 13, 2013 | 08:10AM EST
  25. Benzinga's Top Pre-Market Losers

    Benzinga | Feb. 4, 2013 | 01:22AM EST
  26. UPDATE: Wedbush Raises PT to $5 on Xoma on Gevokizumab Initial Efficacy

    Benzinga | Jan. 7, 2013 | 07:14AM EST
  27. XOMA Says Sevier Initiated Proof-of-Concept Gevokizumab Study for Acute Coronary Syndrome Patients

    Benzinga | Nov. 29, 2012 | 01:25AM EST
  28. XOMA Corp (XOMA) CFO & VP Finance Fred Kurland sells 9,111 Shares

    GuruFocus | Nov. 15, 2012 | 04:35AM EST
  29. XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis

    Benzinga | Sep. 27, 2012 | 07:15AM EST
  30. UPDATE: XOMA Receives Orphan Drug Designation From FDA for Gevokizumab

    Benzinga | Aug. 22, 2012 | 10:55AM EST
  31. XOMA Ltd. Reports Operating Results (10-Q)

    GuruFocus | Aug. 7, 2012 | 13:33PM EST
  32. CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility; Terms Not Disclosed

    Benzinga | Jul. 31, 2012 | 02:04AM EST
  33. Oncobiologics Announces Agreement To Utilize XOMA's Fully Human Antibody Libraries For Discovery Platform

    Benzinga | Jul. 30, 2012 | 04:08AM EST
  34. Health Care Sector Wrap

    FoxBusiness | Jul. 6, 2012 | 10:51AM EST
  35. Benzinga's Top Initiations

    Benzinga | Jun. 28, 2012 | 01:51AM EST
  36. Earnings Scheduled For March 6

    Benzinga | Mar. 5, 2012 | 20:58PM EST
  37. End-of-Day Market Summary for January 17, 2012

    Benzinga | Jan. 17, 2012 | 09:16AM EST
  38. Xoma Shares Down After Job Cuts and One Time Charges Announced

    Benzinga | Jan. 13, 2012 | 06:05AM EST
  39. Benzinga's Microcap Movers for Thursday January 5, 2012

    Benzinga | Jan. 5, 2012 | 13:24PM EST
  40. XOMA Streamlines Operations to Invest in Value-Creating Activities; Cuts 34% of Workforce

    Benzinga | Jan. 5, 2012 | 05:45AM EST
  41. XOMA Corporation New CEO Says Company Expects to Initiate Global Gevokizumab Phase 3 Program in Q2 of 2012

    Benzinga | Jan. 5, 2012 | 05:38AM EST
  42. XOMA Appoints John Varian as Chief Executive Officer

    Benzinga | Jan. 5, 2012 | 05:30AM EST
  43. XOMA Will Move Its Corporate Domicile to Delaware

    Benzinga | Dec. 30, 2011 | 09:05AM EST
  44. XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

    Benzinga | Dec. 21, 2011 | 01:05AM EST
Trading Center